Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Jul;78(1):319–322. doi: 10.1172/JCI112568

Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.

S Hirschel-Scholz, J Caverzasio, R Rizzoli, J P Bonjour
PMCID: PMC329564  PMID: 3013941

Abstract

The Rice-500 Leydig cell tumor (LCT) in Fischer rats is a model of humoral hypercalcemia of malignancy (HHM). In this model, the elevation of plasma calcium (Ca) does not result merely from an increased bone resorption, but also from an enhanced tubular Ca reabsorption (TRCa). We investigated the hypocalcemic response to WR-2721 [S-2,2-(3-aminopropylamino)-, ethylphosphorothioic acid] in LCT-bearing Fischer rats. WR-2721 is a potent inhibitor of normal and aberrant parathyroid hormone (PTH) secretion. Moreover, it exerts a PTH-independent inhibitory effect on TRCa. In hypercalcemic LCT-bearing rats WR-2721 induced a fall in plasma Ca from 3.24 +/- 0.12 to 2.66 +/- 0.23 mmol/liter within 2 h after one single injection of 0.7 mmol/kg body wt. The decrement in plasma Ca was associated with a marked increase in urinary Ca excretion, indicating an inhibition of TRCa. The elevated urine cyclic AMP of LCT-bearing rats, however, was not altered by WR-2721 treatment. These results suggest that in this HHM model, WR-2721 can normalize calcemia through its PTH-independent inhibitory effect on TRCa. WR-2721 could therefore be an effective drug to treat human hypercalcemia of malignancy, particularly in those tumors wherein a markedly enhanced renal Ca reabsorption contributes to the elevation of the plasma Ca level.

Full text

PDF
319

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Attie M. F., Fallon M. D., Spar B., Wolf J. S., Slatopolsky E., Goldfarb S. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells. J Clin Invest. 1985 Apr;75(4):1191–1197. doi: 10.1172/JCI111815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berger M. E., Golub M. S., Sowers J. R., Brickman A. S., Nyby M., Troyer H., Rude R. K., Singer F. R., Horst R., Deftos L. J. Hypercalcemia in association with a Leydig cell tumor in the rat: a model for tumor-induced hypercalcemia in man. Life Sci. 1982 May 3;30(18):1509–1515. doi: 10.1016/0024-3205(82)90237-5. [DOI] [PubMed] [Google Scholar]
  3. Brown B. L., Albano J. D., Ekins R. P., Sgherzi A. M. A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate. Biochem J. 1971 Feb;121(3):561–562. doi: 10.1042/bj1210561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Glover D. J., Shaw L., Glick J. H., Slatopolsky E., Weiler C., Attie M., Goldfarb S. Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid. Ann Intern Med. 1985 Jul;103(1):55–57. doi: 10.7326/0003-4819-103-1-55. [DOI] [PubMed] [Google Scholar]
  5. Glover D., Riley L., Carmichael K., Spar B., Glick J., Kligerman M. M., Agus Z. S., Slatopolsky E., Attie M., Goldfarb S. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). N Engl J Med. 1983 Nov 10;309(19):1137–1141. doi: 10.1056/NEJM198311103091901. [DOI] [PubMed] [Google Scholar]
  6. Hirschel-Scholz S., Caverzasio J., Bonjour J. P. Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent. J Clin Invest. 1985 Nov;76(5):1851–1856. doi: 10.1172/JCI112178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hirschel-Scholz S., Jung A., Fischer J. A., Trechsel U., Bonjour J. P. Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma. Clin Endocrinol (Oxf) 1985 Sep;23(3):313–318. doi: 10.1111/j.1365-2265.1985.tb00229.x. [DOI] [PubMed] [Google Scholar]
  8. Ibbotson K. J., D'Souza S. M., Ng K. W., Osborne C. K., Niall M., Martin T. J., Mundy G. R. Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science. 1983 Sep 23;221(4617):1292–1294. doi: 10.1126/science.6577602. [DOI] [PubMed] [Google Scholar]
  9. Ibbotson K. J., D'Souza S. M., Smith D. D., Carpenter G., Mundy G. R. EGF receptor antiserum inhibits bone resorbing activity produced by a rat Leydig cell tumor associated with the humoral hypercalcemia of malignancy. Endocrinology. 1985 Jan;116(1):469–471. doi: 10.1210/endo-116-1-469. [DOI] [PubMed] [Google Scholar]
  10. Insogna K. L., Stewart A. F., Vignery A. M., Weir E. C., Namnum P. A., Baron R. E., Kirkwood J. M., Deftos L. M., Broadus A. E. Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology. 1984 Mar;114(3):888–896. doi: 10.1210/endo-114-3-888. [DOI] [PubMed] [Google Scholar]
  11. Martodam R. R., Thornton K. S., Sica D. A., D'Souza S. M., Flora L., Mundy G. R. The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int. 1983 Jul;35(4-5):512–519. doi: 10.1007/BF02405086. [DOI] [PubMed] [Google Scholar]
  12. Mundy G. R., Ibbotson K. J., D'Souza S. M. Tumor products and the hypercalcemia of malignancy. J Clin Invest. 1985 Aug;76(2):391–394. doi: 10.1172/JCI111984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ralston S. H., Fogelman I., Gardner M. D., Dryburgh F. J., Cowan R. A., Boyle I. T. Hypercalcaemia of malignancy: evidence for a nonparathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci (Lond) 1984 Feb;66(2):187–191. doi: 10.1042/cs0660187. [DOI] [PubMed] [Google Scholar]
  14. Rice B. F., Ponthier R. L., Jr, Miller M. C., 3rd Hypercalcemia and neoplasia: a model system. Endocrinology. 1971 May;88(5):1210–1216. doi: 10.1210/endo-88-5-1210. [DOI] [PubMed] [Google Scholar]
  15. Rice B. F., Roth L. M., Cole F. E., MacPhee A. A., Davis K., Ponthier R. L., Sternberg W. H. Hypercalcemia and neoplasia. Biologic, biochemical, and ultrastructural studies of a hypercalcemia-producing Leydig cell tumor of the rat. Lab Invest. 1975 Oct;33(4):428–439. [PubMed] [Google Scholar]
  16. Rodan S. B., Insogna K. L., Vignery A. M., Stewart A. F., Broadus A. E., D'Souza S. M., Bertolini D. R., Mundy G. R., Rodan G. A. Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest. 1983 Oct;72(4):1511–1515. doi: 10.1172/JCI111108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sica D. A., Martodam R. R., Aronow J., Mundy G. R. The hypercalcemic rat Leydig cell tumor--a model of the humoral hypercalcemia of malignancy. Calcif Tissue Int. 1983 May;35(3):287–293. doi: 10.1007/BF02405048. [DOI] [PubMed] [Google Scholar]
  18. Spiegel A. M., Saxe A. W., Deftos L. J., Brennan M. F. Humoral hypercalcemia caused by a rat Leydig-cell tumor is associated with suppressed parathyroid hormone secretion and increased urinary cAMP excretion. Horm Metab Res. 1983 Jun;15(6):299–304. doi: 10.1055/s-2007-1018700. [DOI] [PubMed] [Google Scholar]
  19. Tam C. S., Heersche J. N., Santora A., Spiegel A. M. Skeletal response in rats following the implantation of hypercalcemia-producing Leydig cell tumors. Metabolism. 1984 Jan;33(1):50–53. doi: 10.1016/0026-0495(84)90161-6. [DOI] [PubMed] [Google Scholar]
  20. Troyer H., Sowers J. R., Babich E. Leydig cell tumor induced hypercalcemia in the Fischer rat: morphometric and histochemical evidence for a humoral factor that activates osteoclasts. Am J Pathol. 1982 Sep;108(3):284–290. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES